Literature DB >> 1714936

Fibrinolytic response to tumor necrosis factor in healthy subjects.

T van der Poll1, M Levi, H R Büller, S J van Deventer, J P de Boer, C E Hack, J W ten Cate.   

Abstract

Tumor necrosis factor (TNF) may be involved in the disturbance of the procoagulant-fibrinolytic balance in septicemia, leading to microvascular thrombosis. To assess the dynamics of the fibrinolytic response to TNF in humans, we performed a crossover saline-controlled study in six healthy men, investigating the effects of a bolus intravenous injection of recombinant human TNF (50 micrograms/m2) on the stimulation and inhibition of plasminogen activation as well as on plasmin activity and inhibition. TNF induced a brief fourfold increase in the overall plasma plasminogen activator (PA) activity peaking after 1 h (p less than 0.0001), which was associated with rises in the antigenic levels of urokinase-type plasminogen activator (p less than 0.0001) and tissue-type plasminogen activator (p less than 0.0001). Plasminogen activator inhibitor type I antigen remained unchanged in the first hour, but showed a rapid eightfold increase thereafter (p less than 0.0001), which coincided with the decrease in PA activity. Generation of plasmin activity in the first hour was signified by an 11-fold rise in D-dimer levels (p less than 0.0001); inhibition of plasmin was reflected by a 36-fold rise in plasmin-alpha 2 antiplasmin complexes (p less than 0.0001), as well as by a transient 16% decrease in alpha 2-antiplasmin activity (p less than 0.01). In conclusion, TNF induced an early activation of the fibrinolytic system becoming maximal in 1 h, with a rapid inhibition thereafter. Earlier observations in the same subjects showed sustained coagulation activation for 6-12 h. The observed disbalance between the procoagulant and fibrinolytic mechanisms after TNF injection confirms the in vivo relevance of the effects of TNF on vascular endothelium in vitro and may explain the tendency towards microvascular thrombosis in septicemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714936      PMCID: PMC2118940          DOI: 10.1084/jem.174.3.729

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1.

Authors:  M P Bevilacqua; R R Schleef; M A Gimbrone; D J Loskutoff
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

Review 2.  Cachectin/tumour necrosis factor.

Authors:  K J Tracey; H Vlassara; A Cerami
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

3.  Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine.

Authors:  M Hanss; D Collen
Journal:  J Lab Clin Med       Date:  1987-01

4.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways.

Authors:  S J van Deventer; H R Büller; J W ten Cate; L A Aarden; C E Hack; A Sturk
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

5.  Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor.

Authors:  E M Scarpati; J E Sadler
Journal:  J Biol Chem       Date:  1989-12-05       Impact factor: 5.157

6.  Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans.

Authors:  K A Bauer; H ten Cate; S Barzegar; D R Spriggs; M L Sherman; R D Rosenberg
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

7.  Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo.

Authors:  V W van Hinsbergh; T Kooistra; E A van den Berg; H M Princen; W Fiers; J J Emeis
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

8.  Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.

Authors:  A F Suffredini; P C Harpel; J E Parrillo
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

9.  Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.

Authors:  P Holvoet; H Cleemput; D Collen
Journal:  Thromb Haemost       Date:  1985-10-30       Impact factor: 5.249

10.  Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.

Authors:  R R Schleef; M P Bevilacqua; M Sawdey; M A Gimbrone; D J Loskutoff
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

View more
  31 in total

Review 1.  Peritoneal damage: the inflammatory response and clinical implications of the neuro-immuno-humoral axis.

Authors:  Tarik Sammour; Arman Kahokehr; Mattias Soop; Andrew G Hill
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

2.  Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha.

Authors:  C Fearns; D J Loskutoff
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 3.  Tumour necrosis factor and Crohn's disease.

Authors:  S J Van Deventer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 4.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

Review 5.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 6.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

7.  Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans.

Authors:  Tom van der Poll; Marcel Levi; Jerry A Nick; Edward Abraham
Journal:  Am J Respir Crit Care Med       Date:  2005-03-04       Impact factor: 21.405

8.  Streptococcus sanguis-induced platelet clotting in rabbits and hemodynamic and cardiopulmonary consequences.

Authors:  M W Meyer; K Gong; M C Herzberg
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

Authors:  K J Parlevliet; I J ten Berge; S L Yong; J Surachno; J M Wilmink; P T Schellekens
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  Lactobacillus casei modulates the inflammation-coagulation interaction in a pneumococcal pneumonia experimental model.

Authors:  Cecilia Haro; Julio Villena; Hortensia Zelaya; Susana Alvarez; Graciela Agüero
Journal:  J Inflamm (Lond)       Date:  2009-10-16       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.